Peptidylprolyl isomerases have been implicated in chromatin regulation through their association with histones, chromatin-modifying enzymes and DNA-binding transcription factors. As with other posttranslational modifications to proteins, a mechanistic understanding of the regulation of biological processes is fostered by loss-of-function studies both in vitro and in vivo. For peptidylprolyl isomerases, this can be accomplished with small-molecule inhibitors with high affinity for the isomerase active site or by mutation of amino acid residues that contribute to catalysis. In the present article, we review caveats to each of these approaches, and place emphasis on the thorough characterization of loss-offunction mutations in FKBPs (FK506-binding proteins). Using a case study of mutagenesis of the nuclear FKBP25 peptidylprolyl isomerase enzyme, we demonstrate that certain mutations generate a loss-offunction phenotype because they induce a complete loss of the FKBP domain fold, whereas other mutations are 'surgical' in that they ablate catalytic isomerase activity, while maintaining domain structure. Peptidylprolyl isomerases are thought to have both catalytic and non-catalytic functions, but differentiating between these mechanisms has proved to be challenging. The domain-destabilizing and surgical mutants described will facilitate the characterization of these two reported functions of peptidylprolyl isomerases.
Introduction
The role of peptidylprolyl isomerization as a non-covalent post-translational mechanism of protein regulation has been observed for several systems in recent years. Proline can adopt both cis and trans conformations within the context of a protein, whereby the ω angle of the peptide bond differs by 180
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limiting step in the folding of proteins, PPIases serve to facilitate de novo protein folding. However, the biological functions of PPIases extend beyond simple protein chaperoning: a number of enzymes with PPIase activity have been implicated in a spectrum of cellular processes including receptor activity, cell signalling, protein stability, gene regulation, and the epigenetic regulation of histones and chromatin [1] [2] [3] [4] [5] [6] . A reasonable assumption is that, in these systems, protein function is regulated by the conformation of key proline residues and thus affected by PPIase activity. Although in general this model is supported by current literature, some PPIases can regulate biological processes independently of their catalytic isomerase function (see below). Discriminating between catalytic (i.e. prolyl isomerization) and non-catalytic (i.e. binding) contributions of PPIases has proven to be a significant challenge.
Parvulins, Cyps (cyclophilins) and FKBPs (FK506-binding proteins) are three distinct PPIase families. The parvulins represent the smallest family (one to two proteins per proteome) and have been the most studied. The parvulin Pin1 mainly localizes to the nucleus and is the only essential PPIase in yeast [7, 8] . Pin1 also represents the only PPIase with a defined consensus recognition motif, selectively isomerizing peptide bonds between a phosphorylated serine/threonine residue and a proline residue (pS/T-P) [9] . This substrate motif is required for both binding to the WW domain of Pin1, and the isomerization of the peptide by the parvulin domain. In contrast with the parvulin family, multiple Cyps and FKBPs are found in each eukaryotic proteome [10, 11] . Prolyl isomerization by these PPIases shows no dependence on substrate phosphorylation or absolute amino acid sequence. This property raises the question of how Cyp and FKBP PPIases locate substrates.
Accessory domains in PPIases: a recruitment surface?
The lack of obligate primary sequence specificity for the PPIase domains of Cyp and FKBP enzymes may be in part counterbalanced by additional domains present within these proteins that are available for selective recruitment of targets. As an example, the histone chaperones Fpr4, AtFKBP53 (Arabidopsis thaliana FKBP53) and Cyp71 each have an accessory domain that mediates interaction with histone proteins [4, 6, 12] and would therefore limit the PPIase to available proline residues exposed to the catalytic domain during the assembly, regulation or disassembly of the nucleosome. However, not all accessory domains exhibit a similar role devoted to targeting the PPIase activity. Conversely, in some instances, the catalytic isomerase activity may precede binding of an accessory domain. This is the case for the RRM (RNA-recognition motif) domain of Cyp33, which interacts with the H3 Lys 4 methyltransferase MLL1 (mixed lineage leukaemia 1) after the Cyp domain isomerizes a key proline residue of MLL1 [13] .
Small single-domain PPIases (i.e. yeast Cpr1,2 and Fpr1,2) lack accessory domains, but nevertheless interact with distinct sets of proteins [14, 15] and have seemingly discrete functions as implied from genetic interactions [16] . Similarly, small PPIases from higher organisms display non-overlapping functions [11] . This implies that catalytic or interaction specificity can be attributed to differences in the Cyp or FKBP domain itself. Indeed, the solution structures of 15 human Cyp domains reveals variety in surface charges outside the proline-binding active site [17] . An important corollary of this observation is that the 'catalytic' Cyp, FKBP and parvulin domains may have important non-catalytic functions, serving a role such as a protein scaffold [18] . There are cases where effects of a PPIase are dependent on Cyp/FKBP domains, but not the intrinsic catalytic activity. For example, FKBP52 promotes steroid receptor potentiation in vivo; however, mutations affecting catalytic activity do not decrease potentiation [19] . The presence of a loop adjacent to the catalytic pocket in FKBP52 is responsible for receptor interactions and activation, revealing an isomerase-independent role for this PPIase domain. Similarly, a catalytically inert mutant of yeast Fpr1 is able to rescue a synthetic growth defect of fpr1-deficient yeast [20] , and the ability of FKBP25 to promote the degradation of MDM2 (murine double minute 2) is insensitive to the FKBP inhibitor rapamycin. Taken together, these studies illustrate that catalytic domains of PPIases can have functions separate from enzymatic PPIase activity.
The need to discriminate between PPIase-dependent and -independent functions requires tools that can accurately target one of these two properties within given PPIases. Currently, the main approach to study the catalytic and non-catalytic functions has been the use of small-molecule inhibitors and loss-of-function point mutations. As described below, neither method is without drawbacks.
Chemical and genetic inhibition of FKBP and Cyp domains
The use of small molecules to inhibit Cyps and FKBPs were key to their original discovery because of their interaction with the immunosuppressive drugs CsA (cyclosporin A) and FK506 respectively [21] . Since these drugs effectively abolish catalytic PPIase activity, they are frequently used as loss-offunction tools. However, three significant issues arise when using inhibitors to identify PPIase-dependent functions.
First, considerable portions of the bound FK506 or CsA molecules protrude from the active-site pocket. This can potentially inhibit subsequent protein-protein interactions that occur with regions near the catalytic pocket [22] [23] [24] . Thus, in addition to blocking prolyl isomerization, small-molecule inhibitors may result in a loss of protein binding to the active site or regions near to it. Secondly, part of the exposed portion of the bound inhibitor can provide a platform for novel and atypical interactions with subsequent gain-of-function effects. This has been observed with FKBP12-FK506 and CypA-CsA complexes: these ternary complexes acquire the ability to inhibit the phosphatase calcineurin, preventing the activation of T-cells [21] . Similarly, FKBP12-rapamycin complexes, but not FKBP12 alone, can inhibit mTOR (mammalian target of rapamycin), leading to halted cell-cycle progression [25] . Thirdly, although these inhibitors do discriminate FKBPs from Cyps, they cannot effectively resolve between individual members of the FKBP or Cyp families found in most tissues and cells. Using inhibitors in complex mixtures is unable to provide insight into the involvement of an individual PPIase enzyme, and therefore caution needs to be taken when using inhibitors in these circumstances.
To overcome the limitations of PPIase inhibitors, mutations abolishing catalytic activity have been used to determine the role of specific enzymes within a given family and to identify isomerization-dependent functions. Figure 1 shows the structure of the FKBP domain of FKBP25 (PDB code 1PBK) bound to rapamycin, which has a pseudo-proline peptide thought to mimic substrates. The strength of this approach is that these mutations permit the clear study of an individual PPIase, but this method has important caveats that are infrequently addressed: even conservative mutations can potentially disrupt non-catalytic functions, and indeed this is the case for Fpr1 [24] . Furthermore, the structural consequences of loss-of-function mutations are not always explored. We discuss this consequence in detail below.
Targeted mutagenesis of the FKBP domain of FKBP25: an illustrative case study
A number of FKBP and Cyp PPIases are localized to the nucleus [10] . Owing to this distribution alone, these enzymes are likely to have regulatory roles rather than de novo protein folding or chaperone functions. As a consequence, they should also have specific protein clientele instead of a broad range of protein targets. The human PPIase FKBP25 has been shown to localize to the nucleus and associate with nuclear and nucleolar proteins including HDACs (histone deacetylases), protein kinase CK2 and nucleolin [26, 27] . Whereas FKBP25 can promote YY1 (Yin Yang 1) DNA binding, this effect does not involve prolyl isomerization [27] . Similarly, FKBP25 promotes p53 activity by promoting MDM2 autoubiquitination and degradation [28] . Although this effect requires the FKBP domain, it is independent of catalytic activity as judged by rapamycin treatment in vivo. Hence, despite strong evidence for the involvement of FKBP25 in chromatin biology, a role for its PPIase activity has remained elusive.
To determine whether the PPIase activity of FKBP25 is important for its regulation of YY1, MDM2 and potentially other interacting proteins, mutants with diminished catalytic activity would complement small-molecule inhibitor approaches. The yeast orthologue of FKBP25 is Fpr4: these FKBP catalytic domains have a similar charge distribution, and predicted basic surface features. Like its human orthologue, there is evidence supporting a role for Fpr4 as a nuclear enzyme, as it has both histone chaperone [5] and histone PPIase activities [4] . [4, 29] , the analogous mutation in FKBP25 (F145A) would also be expected to reduce prolyl isomerization. This conserved side chain is directed towards the catalytic pocket ( Figure 1A) , and has been used previously in the study of FKBPs ( Figure 1B) . It is interesting to note that mutations at this position have different consequences depending on the FKBP protein: FKBP12 F36L has normal PPIase activity [31] , whereas FKBP52 F67Y is completely inactive [19] . The fact that FKBP12 F36L still has activity may be the result of the hydrophobic leucine residue at this position. Whether mutation to a polar tyrosine residue as in FKBP52 destroys activity has not been explored. In support of FKBP25 being closely related to Fpr4 in yeast, this position is also required for activity of FKBP25: in a chymotrypsin-coupled peptide isomerization assay (Figure 2A ), FKBP25 F145A is catalytically inactive. As mentioned above, the structural consequences of many inactivating PPIase mutations are not known.
During purification of recombinant FKBP25 proteins, strikingly distinct elution profiles of wild-type and F145A FKBP25 on size-exclusion chromatography columns are observed. Specifically, FKBP25 F145A elutes at a molecular mass approximately double that of the wild-type form ( Figure 2B ). This species probably represents a cysteine dimer since FKBP25 F145A treated with a fresh excess of TCEP [tris-(2-carboxyethyl)phosphine] migrates predominantly as a monomer with an apparent molecular mass of 27 kDa. There is a single cysteine residue (Cys 133 ) in FKBP25, and the structure of the PPIase domain (PDB code 1PBK) reveals that it is buried in the hydrophobic core of this domain. Thus the F145A mutation must expose this amino acid. This could be a consequence of local disruption of a β-strand or a more widespread domain unfolding. Consistent with a large-scale change in structure of the C-terminal FKBP domain, digestion with trypsin reveals that FKBP25 F145A is significantly more susceptible to proteolysis than the wild-type ( Figure 2C ), which is supported by HSQC (heteronuclear single-quantum coherence) NMR of FKBP25 and FKBP25 F145A ( Figure 2D ). This reveals that, indeed, the FKBP domain of the FKBP25 F145A mutant is unfolded as the amide shifts of the catalytic domain converge on 8 p.p.m. to 8.4 p.p.m., which are characteristic of an unstructured peptide ( Figure 2D ). Importantly, cross-peaks that correspond to the N-terminus are not affected by this mutation ( Figure 2D) .
Phe→Ala mutations at this conserved position in the FKBP pocket have been used in other members of the FKBP family, notably Fpr4. By contrast, the F323A mutation does not disrupt the fold of Fpr4. Kuzuhra and Horikoshi [29] found that, whereas removal of the C-terminal FKBP domain of Fpr4 has a gain-of-function in histone chaperone assays, the F323A mutant behaves as wild-type, which strongly suggests that the FKBP domain must be correctly folded in vivo.
The case study of the FKBP25 catalytic domain, and previous FKBP studies [19, 31, 32] reveal that the FKBP domain is differentially susceptible to mutations that alter the hydrophobic features of the active site. These results emphasize the importance of structurally characterizing FKBP mutations that ablate catalysis, as some mutations may completely disrupt the fold of the FKBP domain. This is critical when attempting to attribute effects to FKBP prolyl isomerization compared with non-catalytic functions, such as protein interactions.
The FKBP25 F145A mutation is catalytically inactive because it destabilizes the entire FKBP domain. Thus effects of this mutation in vitro or in vivo could be attributed to catalytic or non-catalytic functions. A logical question then is whether mutations that disrupt catalytic peptidylprolyl isomerization, but maintain the general FKBP fold, are possible. Two FKBP25 tyrosine residues (Tyr 135 and Tyr 198 ) are among highly conserved residues comprising the catalytic FKBP pocket ( Figure 1A) . Notably, both side chains are directed towards the active site, and make contact with the rapamycin pseudosubstrate in the co-crystal structure (PDB code 1PBK). In fact, Tyr 198 hydrogen-bonds directly with the carbonyl oxygen of the substrate peptide bond to be isomerized, whereas Tyr 135 is located in the vicinity of amino acids that would be downstream of the substrate proline residue. Consistent with their involvement in catalysis, mutation of the equivalent conserved residues in FKBP12 (Y26F and Y82F) reduces PPIase activity. Indeed, mutation of these sites in FKBP25 has a similar effect: the conservative mutations Y135F and Y198F result in a loss of catalytic activity in vitro ( Figure 3A) .
However, unlike the FKBP F145A mutation, FKBP25 Y135F and Y198F proteins are properly folded. Nonreducing SDS/PAGE is a simple assay that can readily detect FKBP25 cystine dimers generated upon domain unfolding ( Figure 3B ). In this assay, greater than 95 % of wild-type FKBP25 migrates as a monomer, with trace amounts of dimer detectable. As observed previously in size-exclusion chromatography, mutation of F145A migrates as a mixture of monomer and cystine-linked dimer. By contrast, FKBP25 Y135F and Y198F proteins migrate exclusively as monomeric species in non-reducing SDS/PAGE. In support of this, HSQC NMR of these mutants confirms that these proteins are correctly folded ( Figure 3C ). These data demonstrate that these mutations destroy PPIase activity without disrupting the major fold of the FKBP25.
The utility of discrete and destabilizing mutations in the study of FKBPs
PPIases have emerged as important regulators of cellular functions including the regulation of chromatin dynamics and transcription. However, for many PPIase enzymes, it has been challenging to distinguish between the catalytic (i.e. prolyl isomerization) and non-catalytic (i.e. protein binding or other) contributions of PPIase domains. Inhibition of PPIase activity can been accomplished in two ways: smallmolecule inhibitors and domain mutagenesis; however, each present unique challenges. Ideally, in order to attribute effects of PPIases to PPIase activity, the use of small-molecule inhibitors and loss-of-function mutations should be used. The case study of FKBP25 illustrates that mutations that ablate catalysis in vitro should be structurally characterized. This is because at least some loss-of-catalysis mutations, such as F145A in FKBP25, induce a domain-wide loss of structure. Such gross changes will also affect any noncatalytic functions of PPIase domains, and therefore effects of these mutants in vivo or in vitro could also be due to lost protein interactions, or other yet-to-be determined roles for the domain. Indeed, as discussed in the Introduction, many examples of such non-catalytic functions are available. However, the use of domain-destabilizing mutants should not be avoided altogether. When used in conjunction with more surgical catalytically dead mutants, such as FKBP25 Y135F and Y198F, investigators may finally be in a position to dissect between catalytic and non-catalytic functions of PPIases, as non-catalytic functions should be sensitive to the former, but not the latter, mutations.
The identification of key tyrosine residues also provides insight into possible regulatory mechanisms for the catalytic activity of FKBPs in general. As previously stated, tyrosine residues at these positions in the FKBP fold are highly conserved, thus the phosphorylation at these sites may serve as a regulatory role. In support of this, FKBP25 Tyr 198 has been identified to be phosphorylated during mitosis [33] ; however, the functional significance of this has yet to be explored.
Despite the identification of several interacting proteins, substrates for FKBP25 PPIase activity remain elusive. This is representative of most FKBP and Cyp enzymes in general. Whereas the ability of FKBP25 to stimulate MDM2 autoubiquitination appears to be independent of catalytic activity, these experiments were performed in vivo and were hence subject to indirect effects of rapamycin treatment for 2-6 h. It will be interesting to see whether the folded FKBP domain and/or its PPIase activity is required to promote MDM2 autoubiquitination in vitro in the absence of confounding factors, such as mTOR, that may converge on MDM2 and p53 levels. The FKBP mutations described in the present article will be of use for these studies, as well as the relationship between FKBP25 and its interacting proteins, which include CK2 and HDACs, as well as the multifunctional nucleolin protein. Finally, analogous mutations on other FKBPs and Cyp enzymes are needed to help decipher the biological functions of these highly conserved domains that possess both enzymatic and nonenzymatic functions. 
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